A novel prostacyclin receptor agonist, selexipag
ZHANG Xin-fang
SUN Hui-juan
ZHU Mei-hua
WANG Li-li
LIU Zheng-ping
ZHANG Jian-qiang
Abstract：Selexipag belongs to a class of drugs called oral selective prostacyclin receptor agonists.The drug acts by relaxing muscles in the walls of blood vessels to dilate blood vessels and decrease the elevated pressure in the vessels supplying blood to the lungs.In December 2015,selexipag was approved by the standard approval process of the US FDA to treat adults with pulmonary arterial hypertension (PAH).Selexipag was shown to be effective in reducing hospitalization rate for PAH and reducing the risk of disease progression compared to placebo.In this article,the mechanism,pharmacokinetics,pharmacodynamics,clinical studies,dosage and administration,drug interactions,safety,and use in special populations of selexipag were reviewed.
Keywords：prostacyclin receptor agonistpulmonary arterial hypertensionselexipag
Publication Date：2016-01-01
Online Publishing Date：2026-08-14(First online date of this platform, not the publication date of the document)